-
Blood: Chromosome 20 loss is a feature of degenerative large cell lymphoma associated with breast implants.
Time of Update: 2020-10-03
addition, CNA analysis can be used as a parameter for future diagnostic tests for women with breast implants to distinguish between serum swelling caused by BIA-ALCL and other causes of serotonia aggregation, such as infection or trauma.
-
The antibody drug Polivy, which targets CD79a, is recommended by NICE for the treatment of relapsed or resuscable large B-cell lymphoma.
Time of Update: 2020-10-03
The National Institute for Health and Care Excellence (NICE) recommends combining Roche's antibody drug polyvy (polatuzumab vedotin) with rituximab and bendamustine to treat diffuse large B-cell lymphoma (DLBCL).
-
Blood: The neurotransmitter subject GABBBR1 directly regulates the proliferation and function of hematologic stem/progeny cells.
Time of Update: 2020-10-03
hematopoietic dry/progenitor cells (HSPCs) express neurotransmitter subjects, such as g-amino butyric acid (GABA) type B-type ligand sub-base 1 (GABBR1), suggesting that HSPCs can be regulated directly by neurotransmitters such as GABA in combination with GABBR1.
in-body co-culture, Gabbr1-/-HSPC produced a small number of cells, accompanied by significant differentiation defects and B-cell line amplification.
-
This year's biggest pharmaceutical acquisition: Johnson and Johnson's $6.5 billion all-cash acquisition of Momenta.
Time of Update: 2020-10-03
deal will give Johnson and Johnson access to a combination of Momenta autoimmune disease drugs, including the anti-FcRn antibody nipocalimab, which is currently being developed to treat the rare neuromuscular disease, severe muscle weakness.
-
J Clin Oncol: Changes in mortality from classic Hodgkin's lymphoma, 2000-2015.
Time of Update: 2020-10-03
study aims to analyze 20,007 patients aged I/II (early) or III/IV (late) cHL who were treated with initial chemotherapy between 2000 and 2015 in the US cancer registry.
treatments for cHL continue to evolve, patients still face an increased risk of non-lymphoma death from a variety of potentially preventable causes.
-
Blood: An individualized method that guides AML patients when to perform hematopoietic stem cell transplants.
Time of Update: 2020-10-03
patients who received CR1, HSCT was used as a time-dependent covariative variable in patients with better risk stratition and NPM1 MRD-negative ELN2017.
, the researchers consolidated ELN 2017, NPM1 MRD and KB scores, spliting 545 CR1 patients into 278 (51.0%) HSCT candidates and 267 (49.0%) single chemotherapy candidates.
-
Blood: The reactive CD8 effect T cells selectively amplification in tissues rich in IL-23 in gastrointestinal GvHD.
Time of Update: 2020-10-03
In this study, Ball and others used traditional and new sequential immune staining and fluid cytometry to carefully observe RA-reactive T-cells in AHST patients' tissues and blood, and to characterization of the effects of RA on the heterogeneic response of human T-cells.
-
Clin Cancer Res: Anti-ICAM1 antibody-drug coupled for potential activity of multiple myeloma.
Time of Update: 2020-10-03
researchers linked anti-ICAM1 monoclonal antibodies to Raoxitin derivatives and tested them in a variety of multiple myeloma cell line, in-place transplant models, and patient samples.
recommend that the toxicity, safety and clinical efficacy of anti-ICAM1 antibody-drug couples should be further evaluated in patients with relapsed or refrmmune multiple myeloma.
-
Blood: The GNAO1 mutation and the ETV6-RUNX1 fusion mutation promote synergy in leukemia.
Time of Update: 2020-10-03
recently published in the journal Blood, researchers sequenced all-exoscopic twins from children with inconsistent fusion of ETV6-RUNX1 (E/R) genes in the paper "Dentification of functional cooperative mutations of GNAO1 in human acute lymphoblastic leukemia." sequencing results found that the R209C mutation of G protein alpha subchio1 is a new risk point for ALL.
E/R fusion, the GNAO1 R209C mutation promotes leukemia by activating the PI3K/Akt/mTOR signal.
-
Acta Neuropathologica: Changes in DNA methylation spectrum in the blood of patients with kerats.
Time of Update: 2020-10-03
, the authors' team analyzed methylation of the entire genome of blood DNA, the most common form of human prion disease, which radiates sCJD.
-
Blood: Plateplate reactive protein-1 promotes hemostation by regulating the camp signal of plate plate plates.
Time of Update: 2020-10-03
plateplates with TSP-1 subject CD36 defects are more sensitive to PGI2/cAMP signals, PDE3A activity is reduced, and is not affected by plateboard sources or purified TSP-1.
-
J Clin Oncol: Patients with advanced Hodgkin's lymphoma who received full metabolic remission after ABVD chemotherapy can safely omit consolidation chemotherapy.
Time of Update: 2020-10-03
The HD 0607 trial (NCT00795613) is designed to study the role of consolidated radiotherapy (cRT) in advanced Hodgkin's lymphoma (cHL) that is fully metabolically relieved after chemotherapy with ammoxin, Bolemycin, chlorpyridoxine and dakabatin (ABVD) with large lymph nodes (LNM).
-
Lancet Oncol: Ointoju single anti-DHAP combination therapy to treat sleeve cell lymphoma.
Time of Update: 2020-10-03
result of the study was a four-cycle combined treatment with negative residues of micro-diseases in the bone marrow.
if the residual negative rate of bone marrow micro-disease is 70% or higher, the combined DHAP of Ointojuzhu is considered effective.
-
Brit J Cancer: Relationship between adult leukemia and long-term air pollution exposure.
Time of Update: 2020-10-03
researchers used data from the Danish National Cancer Registry and air pollution exposure modeled by denmark's DEHM-UBM-AirGIS system to assess whether 1, 5 or 10-year average particulate matter (PM2.5), black carbon (BC), nitrogen dioxide (NO2) and ozone (O3) levels were associated with adult leukemia or its subsype.
-
Blood: BCL6 maintains the survival and self-renewal of AML's original cells, or may be a new therapeutic target.
Time of Update: 2020-10-03
important, inhibiting or knocking out BCL6 in primary AML cells significantly reduced leukemia start-up capacity in mice, indicating that the function of leukemia refilling cells was ablation.
-
Blood: Hereditary alpha-trypsinemia is an effective genetic biomarker of hypertrophic cell hypertrophicity.
Time of Update: 2020-10-03
used PCR to evaluate the TPSAB1 embryo copy number variation of 180 patients with hypertrophic cell hypertrophicity, 180 gender-matched control individuals, 720 other myelin tumor patients, and an additional 61 patients with hypertrophic cell hypertrophicity in another independent validation queue.
-
Blood: Tumor internal and external markers that affect the effectiveness of Bona Twain anti-treatment in B-ALL patients.
Time of Update: 2020-10-03
study, both internal and external factors in tumors can affect a patient's response to Bonathumant anti-treatment.
CD19 mutations are common in patients with CD19-negative recurrence during Bona Twain anti-treatment.
-
Flow: Immune thrombosis in neocooproid pneumonia is associated with respiratory failure and systemic high coagulation.
Time of Update: 2020-10-03
(COVID-19-related microvascular thrombosis in the lungs, kidneys and heart) showed that organ injury and thrombosis characteristics in PATIENTs with COVID-19 were associated with immunothrombosis.
, the study shows that immunothrombosis is a key marker of the severity of COVID-19 disease.
-
Blood: Incredibly, gut bacteria can determine whether susceptible people have leukemia!
Time of Update: 2020-10-03
In this study, researchers used pB-ALL mouse models to demonstrate that microbiome disorders caused by early-life antibiotic treatment were sufficient to induce leukemia in genetically susceptible mice, even without infection stimulation and independent of T-cells.
-
AGING CELL: Long-term dietary restrictions make hematopoietic stem cells younger.
Time of Update: 2020-10-03
Recently, a team of researchers from Nanchang University's Second Affiliated Hospital, published in the journal Age Cell, analyzed the effects of short-term (4 months) and long-term (9 months) treatment of C57BL/6 J mice on the function of HSCs and bone marrow cells in transplantation and undisturbed conditions, starting at 15-18 months of age.
